Carboplatin/Paclitaxel Regimen — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	23	8	20	58	—	—	2003-03
Malignant Breast Neoplasm	Phase4	Phase 4	4	1	2	8	—	—	2007-12
Malignant Lung Neoplasm	Phase3	Phase 3	4	2	7	17	—	—	2003-03
Malignant Esophageal Neoplasm	Phase3	Phase 3	3	1	1	6	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 Amplification1
Carboplatin/Paclitaxel Regimen

Clinical trials

Trials with this intervention (59)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 59 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05061550	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer(NeoCOAST-2)	recruiting	Phase 2	630	AstraZenecaINDUSTRY	12	Sep 23, 2026	clinicaltrials
NCT07836049	PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC	not yet recruiting